查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999352

自動化和封閉式細胞治療處理系統市場：全球市場按產品類型、技術、工藝類型、應用和最終用戶分類的預測——2026-2032年

Automated & Closed Cell Therapy Processing Systems Market by Product Type, Technology, Process Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自動化密封細胞治療處理系統市場價值將達到 12.4 億美元，到 2026 年將成長至 14.3 億美元，到 2032 年將達到 36.3 億美元，複合年成長率為 16.49%。

主要市場統計數據
基準年 2025 12.4億美元
預計年份：2026年 14.3億美元
預測年份 2032 36.3億美元
複合年成長率 (%) 16.49%

簡要概述自動化和密封處理如何改變細胞治療操作、監管預期和臨床準備。

隨著自動化和封閉式流程解決方案從小眾實驗室工具發展成為臨床計畫的基礎架構，細胞治療的治療環境正在迅速演變。平台工程的進步，以及對產品品質一致性和減少人工操作流程日益成長的需求，使得自動化和封閉式系統不再只是為了方便操作，而是成為實現可擴展治療方法的戰略要素。臨床醫生和生產負責人越來越重視流程標準化、污染控制和可追溯性，並將這些視為規劃細胞治療產品線的關鍵要素。

對細胞治療製程的主要系統性變革進行整體情況，優先考慮自動化、污染控制、互通性和長期臨床擴充性。

近年來，隨著研發人員、監管機構和支付方將重點轉向可靠性、擴充性和患者安全，細胞治療生態系統發生了變革性變化。首先，人們越來越重視透過自動化來降低變異性。人工交接和開放式操作方式日益被視為影響療效和一致性的風險因子。其次，封閉式處理架構因其能更有效地控制污染並提高複雜供應鏈的可追溯性而備受關注。

該評估旨在評估近期關稅變化和貿易政策趨勢對供應商策略、採購風險管理和區域供應鏈韌性的影響。

近期影響關稅和貿易的政策決定可能會對全球加工設備的資本投資計畫和供應商策略產生重大影響。關稅調整會改變進口設備和耗材的相對成本競爭力，進而影響新創公司和成熟製造商的採購決策。因此，設備供應商正在重新審視製造地、供應商合約和零件採購，以降低跨境稅收變化帶來的風險。

詳細的細分分析表明，產品類型、臨床應用、分離技術、最終用戶和個人製程能力如何決定採購和驗證的優先事項。

穩健的細分觀點闡明了不同的產品架構、臨床應用、隔離技術、最終用戶和流程類型如何影響採購決策和營運優先順序。產品類型區分了整合多個單元操作的全自動系統和主要用於降低污染風險和人工接觸的封閉式系統，兩者均具有不同的驗證途徑和設施要求。基於應用的細分區分了異體療法（包括造血幹細胞療法、間質幹細胞療法和自然殺手細胞療法）和自體療法（包括CAR-T細胞療法、造血幹細胞療法和間質幹細胞療法），每種應用都有其獨特的處理能力、無菌性和控制歷史要求。

區域趨勢和部署策略解釋了北美和南美、歐洲、中東和非洲以及亞太地區的市場如何影響供應商的方法和臨床實施。

區域趨勢正以不同的方式影響醫療器材的採納路徑、供應商策略和監管預期。在美洲，創新公司和成熟製造商在強調流程控制和臨床安全證據的法規環境下並存，這促進了簡化合規流程和加速院內生產的系統的早期應用。資金籌措環境和臨床卓越中心的集中也為醫療器材供應商和臨床開發商之間的夥伴關係提供了支持。

競爭力和供應商差異化由技術創新、驗證服務、耗材策略和策略臨床夥伴關係關係驅動。

處理系統市場的競爭格局取決於技術創新、售後服務、法規專業知識和夥伴關係模式的綜合作用。領先的供應商透過提供能夠最大限度減少人工操作、支援封閉式工作流程的平台，以及整合增強可追溯性和批次文件記錄的軟體來脫穎而出。設備製造商與臨床試驗機構或合約開發商之間的策略合作十分普遍，這有助於進行實際驗證和迭代產品改進。

為供應商和臨床領導者提供可操作的建議，以透過互通性、驗證一致性和供應彈性來加速安全且可擴展的部署。

產業領導者應優先採取以下幾項切實可行的措施來加速產品推廣應用，同時管控風險。首先，使產品開發藍圖與當前監管要求中關於流程控制和可追溯性的規定保持一致，將減輕下游合格的負擔，並縮短臨床試驗中心和契約製造的部署時間。其次，投資硬體和軟體的模組化和互通性，將使平台能夠支援多種治療模式並整合到不同的臨床試驗環境中，從而提升長期價值。

採用綜合混合方法研究途徑，結合對關鍵相關人員的訪談、技術文件的審查、監管指導的分析以及營運實踐的案例研究。

本分析採用多維度研究方法，結合一手訪談、供應商產品文件、監管指南審查和營運案例研究，確保提供平衡且實用的見解。一手訪談對象涵蓋廣泛的相關人員，包括臨床生產經理、製程工程師、採購經理和法規遵循專家，從而獲得關於決策標準和實施挑戰的實地觀點。此外，還對供應商文件和技術規格進行了深入審查，以評估平台架構、耗材生態系統和軟體功能。

總結了為什麼檢驗、封閉和自動化的工作流程對於創建更安全、更可靠、運作永續的細胞治療項目至關重要。

總之，自動化封閉式細胞治療處理系統的成熟為提高治療一致性、降低污染風險以及擴大先進細胞療法的臨床應用提供了關鍵機會。隨著技術的進步，最成功的機構將優先考慮經過驗證的流程控制、可互操作系統以及強大的服務生態系統。區域差異和貿易政策趨勢凸顯了靈活籌資策略和在地化支援對於維持專案連續性的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：自動化和封閉式細胞治療處理系統市場：依產品類型分類

  • 自動化系統
  • 封閉式系統

第9章：自動化和封閉式細胞治療處理系統市場：依技術分類

  • 離心分離
    • 密度梯度離心
    • 固定角離心分離
    • 擺動斗式離心分離
  • 過濾
    • 微過濾
    • 超過濾
  • 磁選
    • 免疫磁珠分離
    • 順磁分離

第10章：按製程類型分類的自動化和封閉式細胞治療處理系統市場

  • 細胞計數和分析
    • 自動計數
    • 人工計數
  • 細胞分離
    • 離心分離
    • 過濾和分離
    • 磁選
  • 細胞製備
  • 細胞保存
  • 細胞洗滌

第11章：自動化封閉式細胞治療處理系統市場：依應用領域分類

  • 同種
    • 造血幹細胞療法
    • 自然殺手細胞療法
  • 自有住房
    • CAR-T細胞療法
    • 間質幹細胞療法

第12章：自動化封閉式細胞治療處理系統市場：依最終使用者分類

  • 合約研究機構
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第13章：自動化封閉式細胞治療處理系統市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：自動化封閉式細胞治療處理系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：自動化封閉式細胞治療處理系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國自動化封閉式細胞治療處理系統市場

第17章：中國自動化封閉式細胞治療處理系統市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bio-Techne Corporation
  • BioLife Solutions Inc.
  • BioSpherix, Ltd.
  • Cellares Inc.
  • Corning Incorporated
  • Cytiva
  • Danaher Corporation
  • Fresenius SE & Co. KGaA
  • General Electric Company
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Regeneus Ltd.
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific, Inc.
  • Thermogenesis Holdings, Inc.
Product Code: MRR-3A2E844FE4D9

The Automated & Closed Cell Therapy Processing Systems Market was valued at USD 1.24 billion in 2025 and is projected to grow to USD 1.43 billion in 2026, with a CAGR of 16.49%, reaching USD 3.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.24 billion
Estimated Year [2026] USD 1.43 billion
Forecast Year [2032] USD 3.63 billion
CAGR (%) 16.49%

A concise contextual introduction framing how automation and closed processing are reshaping cell therapy operations, regulatory expectations, and clinical readiness

The therapeutic landscape for cellular medicine is evolving rapidly as automated and closed processing solutions move from niche laboratory tools to foundational infrastructure for clinical programs. Advances in platform engineering, coupled with increased demand for consistent product quality and reduced manual handling, have elevated automated systems and closed systems from operational conveniences to strategic enablers of scalable therapies. Clinicians and manufacturing leaders increasingly view process standardization, contamination control, and traceability as nonnegotiable attributes when planning cell therapy pipelines.

Moreover, regulatory agencies worldwide continue to stress the importance of validated processes and robust documentation, which favors technologies that inherently support reproducibility and auditability. In parallel, technology vendors are investing in modular designs and interoperable software ecosystems to accommodate diverse cell types and evolving protocols. This convergence of clinical, regulatory, and engineering priorities is encouraging adoption across both autologous and allogeneic workflows.

Consequently, stakeholders ranging from research institutes to commercial developers must reassess their operations to incorporate closed and automated solutions earlier in the product lifecycle. This introductory analysis frames the critical drivers, common barriers, and decision criteria that influence selection and deployment of processing technologies, establishing the context for deeper segmentation and regional considerations presented in subsequent sections.

Mapping the major systemic shifts in cell therapy processing that prioritize automation, contamination control, interoperability, and long-term clinical scalability

The last several years have witnessed transformative shifts in the cell therapy ecosystem as the priorities of developers, regulators, and payers converge on reliability, scalability, and patient safety. First, there is a growing emphasis on reducing variability through automation; manual hand-offs and open handling are increasingly viewed as sources of risk that can undermine potency and consistency. Second, closed processing architectures are gaining prominence because they provide stronger contamination control and improve traceability across complex supply chains.

At the same time, advances in separation and enrichment technologies have expanded the range of feasible cell modalities, enabling more precise selection and conditioning of target cell populations. These technical improvements are accompanied by a maturing regulatory dialogue that rewards documented process control and integrated quality systems. Financing patterns and partnerships are also shifting, with contract developers and manufacturers evaluating capital allocation toward flexible automated platforms that support multiple product formats.

Transitioning from proof-of-concept to routine clinical manufacture requires addressing workforce competencies, facility design, and interoperability between instruments and informatics systems. As a result, organizations that invest early in validated automation standards and closed workflows position themselves to accelerate clinical throughput while mitigating operational risk. This section maps those systemic changes and explains why they are likely to persist as foundational trends.

Evaluating how recent tariff changes and trade policy dynamics are reshaping supplier strategies, procurement risk management, and regional supply chain resilience

Recent policy decisions affecting tariffs and trade can materially influence capital expenditure planning and supplier strategies for processing equipment sourced globally. Tariff adjustments alter the relative cost competitiveness of imported instruments and consumables, which in turn affects procurement decisions for both early-stage developers and established manufacturers. Equipment vendors are consequently reassessing manufacturing footprints, supplier contracts, and component sourcing to reduce exposure to cross-border tax changes.

For developers and contract manufacturers, tariffs create an incentive to increase local sourcing of critical components and to negotiate longer-term supply agreements that hedge against future policy swings. This trend is accelerating conversations about regionalization of supply chains and the potential need for duplicated inventories to maintain uninterrupted production during periods of trade uncertainty. In parallel, vendors are responding by investing in localized assembly, modular design that accommodates alternate components, and expanded service networks to preserve competitiveness.

Operationally, the indirect effects of tariff shifts-such as delays in equipment deployment, increased lead times for validated consumables, and higher qualification costs for alternative parts-can slow technology adoption. Therefore, procurement and program managers are advised to incorporate tariff sensitivity into procurement risk assessments and supplier qualification plans. Doing so supports continuity of clinical programs and reduces the likelihood of process disruptions tied to trade policy volatility.

Detailed segmentation analysis showing how product types, clinical applications, separation technologies, end users, and discrete process functions determine procurement and validation priorities

A robust segmentation perspective clarifies how different product architectures, clinical applications, separation technologies, end users, and process types influence procurement decisions and operational priorities. Product type distinguishes between fully automated systems that integrate multiple unit operations and closed systems designed primarily to reduce contamination risk and manual exposure, each presenting distinct validation pathways and facility requirements. Application segmentation separates allogeneic approaches-which include hematopoietic stem cell therapy, mesenchymal stem cell therapy, and natural killer cell therapy-from autologous approaches such as CAR T cell therapy, hematopoietic stem cell therapy, and mesenchymal stem cell therapy, with each application imposing unique throughput, sterility, and chain-of-custody demands.

Technology distinctions matter because centrifugation methods, including density gradient, fixed angle, and swing-bucket variants, deliver different trade-offs in recovery and throughput, while filtration options such as microfiltration and ultrafiltration offer alternate profiles for cell concentration and media exchange. Magnetic separation technologies, whether immunomagnetic bead-based or paramagnetic approaches, provide high-specificity enrichment but require tailored reagent workflows and regulatory control strategies. End users span contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, each with divergent procurement cycles, validation capabilities, and tolerance for capital intensity.

Process-type segmentation further refines decision-making: cell counting and analysis operations range from automated counters to manual methods; cell preparation activities include formulation and thawing protocols; separation processes encompass centrifugation, filtration, and magnetic separation; storage solutions address long-term and short-term requirements; and washing operations can be automated or manual. Understanding these layered segment distinctions enables stakeholders to align technology choices with clinical objectives, operational capacity, and regulatory obligations.

Regional dynamics and deployment strategies that explain how Americas, Europe Middle East & Africa, and Asia-Pacific markets influence vendor approaches and clinical adoption

Regional dynamics shape adoption pathways, supplier strategies, and regulatory expectations in distinctive ways. In the Americas, innovators and established manufacturers coexist within a regulatory environment that emphasizes evidence of process control and clinical safety, encouraging early adoption of systems that simplify compliance and accelerate hospital-based manufacturing. Funding environments and a concentration of clinical centers of excellence also support partnerships between instrument vendors and clinical developers.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement ecosystems vary widely, leading vendors to prioritize flexible, modular platforms that can be adapted to local requirements and clinical practice patterns. Capacity constraints in certain countries drive demand for contract manufacturing and service-based models, while larger markets seek integrated solutions that align with regional GMP expectations. In the Asia-Pacific region, rapid expansion of biotech hubs, ambitious national initiatives to build domestic manufacturing capability, and increasing investments in cell therapy clinical trials create strong demand for both cost-effective closed systems and high-throughput automated platforms. Local suppliers and multinational companies compete to offer solutions that align with regional labor dynamics and infrastructure maturity.

Taken together, these geographic differences encourage suppliers to adopt differentiated market strategies: emphasizing localized service and regulatory support in some areas, while promoting scalability and interoperability in others. Companies that tailor product features and commercial approaches to these regional nuances can better support deployment and long-term program sustainability.

Competitive dynamics and vendor differentiation driven by technological innovation, validation services, consumable strategies, and strategic clinical partnerships

Competitive positioning in the processing systems landscape is driven by a combination of technological innovation, after-sales service, regulatory expertise, and partnership models. Leading suppliers differentiate by offering platforms that minimize manual steps and support closed workflows, while also integrating software that enhances traceability and batch documentation. Strategic collaborations between equipment manufacturers and clinical sites or contract developers are common, enabling real-world validation and iterative product improvement.

Service capabilities, including on-site qualification, validation support, and spare-parts logistics, are often decisive factors for procurement committees, particularly for facilities lacking in-house engineering resources. In addition, providers that offer consumable suites and reagent standardization reduce the complexity of qualification and lower the barrier to adoption for resource-constrained end users. Intellectual property around proprietary separation technologies, cartridge designs, and reagent chemistries can create durable differentiation, but such advantages require clear clinical benefit and regulatory alignment to be impactful.

Finally, newer entrants compete by emphasizing affordability, modularity, and open integration with third-party informatics, whereas incumbent vendors leverage established customer bases and regulatory credentials. The competitive landscape rewards organizations that can demonstrate validated performance across diverse cell types, scalable workflows, and comprehensive technical support.

Actionable recommendations for vendors and clinical leaders to accelerate safe, scalable adoption through interoperability, validation alignment, and supply resilience

Industry leaders should prioritize several actionable steps to accelerate adoption while managing risk. First, aligning product development roadmaps with prevailing regulatory expectations for process control and traceability will reduce downstream qualification burdens and improve time-to-deployment at clinical sites and contract manufacturers. Second, investing in modularity and interoperability-both in hardware and software-allows platforms to serve multiple modalities and to integrate into heterogeneous facility environments, thereby increasing long-term value.

Third, expanding localized service networks and establishing regional assembly or component sourcing can mitigate exposure to tariff fluctuations and supply-chain disruptions, while also shortening lead times for critical spares and qualifications. Fourth, vendors and end users should jointly develop standardized validation protocols and interoperable data formats to streamline technology transfer and accelerate adoption across diverse end-user profiles. Fifth, building flexible commercial models that combine capital equipment with consumable subscriptions or outcome-aligned service agreements can lower initial barriers for hospitals and smaller research centers.

Taken together, these recommendations encourage a balanced approach that marries technological excellence with pragmatic operational safeguards, ultimately enabling more reliable and scalable cell therapy manufacturing across the clinical ecosystem.

Comprehensive mixed-method research approach integrating primary stakeholder interviews, technical documentation review, regulatory guidance analysis, and operational case studies

This analysis draws on a multi-method research approach combining primary interviews, vendor product documentation, regulatory guidance review, and operational case studies to ensure balanced and practical insights. Primary interviews were conducted with a cross-section of stakeholders including clinical manufacturing leads, process engineers, procurement managers, and regulatory affairs specialists, enabling a grounded view of decision criteria and implementation challenges. Vendor literature and technical specifications were reviewed to assess platform architectures, consumable ecosystems, and software capabilities.

Regulatory guidance documents and public policy announcements were examined to identify compliance trends and documentation expectations relevant to closed and automated processing systems. Operational case studies provided context on facility design, validation workflows, and human factors considerations, illustrating how technologies perform in near-production environments. Where possible, anonymized examples of technology transfer and qualification timelines were synthesized to highlight common bottlenecks and mitigation strategies.

Throughout the research, findings were triangulated to reduce bias and ensure that product claims align with observed operational realities. The methodology emphasizes practical applicability, enabling decision-makers to translate insights into procurement specifications, validation plans, and strategic roadmaps.

Concluding synthesis on why validated closed and automated workflows are essential to deliver safer, more reliable, and operationally sustainable cell therapy programs

In summary, the maturation of automated and closed cell therapy processing systems represents a pivotal opportunity to improve consistency, reduce contamination risk, and enable broader clinical access to advanced cellular medicines. As technologies evolve, the most successful organizations will be those that prioritize validated process control, interoperable systems, and robust service ecosystems. Regional differences and trade policy dynamics underscore the need for flexible sourcing strategies and localized support to maintain program continuity.

Stakeholders should therefore adopt a holistic perspective that considers not only device performance but also validation burden, consumable ecosystems, and supplier resilience. By aligning procurement decisions with regulatory expectations and operational realities, clinical developers and manufacturers can reduce risk and accelerate the translation of promising therapies into routine care. Ultimately, the integration of automation and closed processing into development and manufacturing pathways will be a decisive factor in delivering reliable, safe, and scalable cell therapies to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated & Closed Cell Therapy Processing Systems Market, by Product Type

  • 8.1. Automated Systems
  • 8.2. Closed Systems

9. Automated & Closed Cell Therapy Processing Systems Market, by Technology

  • 9.1. Centrifugation
    • 9.1.1. Density Gradient Centrifugation
    • 9.1.2. Fixed Angle Centrifugation
    • 9.1.3. Swing Bucket Centrifugation
  • 9.2. Filtration
    • 9.2.1. Microfiltration
    • 9.2.2. Ultrafiltration
  • 9.3. Magnetic Separation
    • 9.3.1. Immunomagnetic Bead Separation
    • 9.3.2. Paramagnetic Separation

10. Automated & Closed Cell Therapy Processing Systems Market, by Process Type

  • 10.1. Cell Counting & Analysis
    • 10.1.1. Automated Counting
    • 10.1.2. Manual Counting
  • 10.2. Cell Separation
    • 10.2.1. Centrifugation Separation
    • 10.2.2. Filtration Separation
    • 10.2.3. Magnetic Separation
  • 10.3. Cell Preparation
  • 10.4. Cell Storage
  • 10.5. Cell Washing

11. Automated & Closed Cell Therapy Processing Systems Market, by Application

  • 11.1. Allogeneic
    • 11.1.1. Hematopoietic Stem Cell Therapy
    • 11.1.2. Natural Killer Cell Therapy
  • 11.2. Autologous
    • 11.2.1. Car T Cell Therapy
    • 11.2.2. Mesenchymal Stem Cell Therapy

12. Automated & Closed Cell Therapy Processing Systems Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes

13. Automated & Closed Cell Therapy Processing Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automated & Closed Cell Therapy Processing Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automated & Closed Cell Therapy Processing Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automated & Closed Cell Therapy Processing Systems Market

17. China Automated & Closed Cell Therapy Processing Systems Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bio-Techne Corporation
  • 18.6. BioLife Solutions Inc.
  • 18.7. BioSpherix, Ltd.
  • 18.8. Cellares Inc.
  • 18.9. Corning Incorporated
  • 18.10. Cytiva
  • 18.11. Danaher Corporation
  • 18.12. Fresenius SE & Co. KGaA
  • 18.13. General Electric Company
  • 18.14. Lonza Group AG
  • 18.15. Merck KGaA
  • 18.16. Miltenyi Biotec B.V. & Co. KG
  • 18.17. Novartis AG
  • 18.18. Pluristem Therapeutics Inc.
  • 18.19. Regeneus Ltd.
  • 18.20. Sartorius AG
  • 18.21. STEMCELL Technologies Canada Inc.
  • 18.22. Terumo Corporation
  • 18.23. Thermo Fisher Scientific, Inc.
  • 18.24. Thermogenesis Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 233. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 235. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 240. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATI